WXXWY:OTC-WuXi Biologics (Cayman) Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.36

Change

-0.09 (-2.61)%

Market Cap

USD 7.10B

Volume

0.33M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 564.56B
CMXHF CSL Limited

N/A

USD 89.03B
CSLLY CSL Ltd

N/A

USD 84.45B
UCBJF UCB SA

N/A

USD 25.40B
UCBJY UCB SA ADR

N/A

USD 24.49B
ARGNF argenx SE

N/A

USD 22.81B
GNMSF Genmab A/S

N/A

USD 18.12B
WXIBF WuXi Biologics

N/A

USD 7.17B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.76B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 5.92B

ETFs Containing WXXWY

CN Xtrackers MSCI All China .. 0.00 % 0.28 %

N/A

USD 5.93M
EEMO Invesco S&P Emerging Mark.. 0.00 % 0.27 %

N/A

USD 6.24M
FXI iShares China Large-Cap E.. 0.00 % 0.74 %

N/A

USD 4.39B
MCHI iShares MSCI China ETF 0.00 % 0.59 %

N/A

USD 5.02B
EMSG DBX ETF Trust - Xtrackers.. 0.00 % 0.00 %

N/A

USD 0.02B
CHIL 0.00 % 0.00 %

N/A

N/A
CEA1:LSE iShares VII Public Limite.. 0.00 % 0.00 %

N/A

USD 2.29B
DBRC:LSE iShares BRIC 50 UCITS 0.00 % 0.00 %

N/A

USD 0.10B
EIMU:LSE iShares Core MSCI EM IMI .. 0.00 % 0.00 %

N/A

USD 19.47B
FXC:LSE iShares China Large Cap U.. 0.00 % 0.00 %

N/A

USD 0.47B
HMAD:LSE HSBC ETFs Public Limited .. 0.00 % 0.00 %

N/A

USD 0.26B
HMCD:LSE HSBC MSCI China UCITS ETF 0.00 % 0.00 %

N/A

USD 0.59B
HMFE:LSE 0.00 % 0.00 %

N/A

N/A
IDFX:LSE iShares China Large Cap U.. 0.00 % 0.00 %

N/A

USD 0.47B
IEEM:LSE iShares MSCI Emerging Mar.. 0.00 % 0.00 %

N/A

USD 4.17B
IFFF:LSE iShares Public Limited Co.. 0.00 % 0.00 %

N/A

USD 0.82B
SAEM:LSE iShares MSCI EM IMI ESG S.. 0.00 % 0.00 %

N/A

USD 3.06B
SEDM:LSE iShares MSCI EM IMI ESG S.. 0.00 % 0.00 %

N/A

USD 3.06B
HMEM:LSE HSBC MSCI Emerging Market.. 0.00 % 0.00 %

N/A

USD 1.99B
HMFD:LSE 0.00 % 0.00 %

N/A

N/A
SUES:LSE iShares Sustainable MSCI .. 0.00 % 0.00 %

N/A

USD 3.31B
SUSM:LSE iShares Sustainable MSCI .. 0.00 % 0.00 %

N/A

USD 3.31B
UB30:LSE UBS MSCI Emerging Markets.. 0.00 % 0.00 %

N/A

USD 0.20M
XCX6:LSE Xtrackers MSCI China UCIT.. 0.00 % 0.00 %

N/A

USD 1.21B
XMME:LSE Xtrackers MSCI Emerging M.. 0.00 % 0.00 %

N/A

USD 5.13B
XX25:LSE Xtrackers FTSE China 50 U.. 0.00 % 0.00 %

N/A

USD 0.11B
XX2D:LSE Xtrackers - FTSE China 50.. 0.00 % 0.00 %

N/A

USD 0.11B
KESG 0.00 % 0.00 %

N/A

N/A
EMXF iShares ESG Advanced MSCI.. 0.00 % 0.00 %

N/A

USD 0.07B
VFEA:LSE Vanguard FTSE Emerging Ma.. 0.00 % 0.00 %

N/A

USD 2.68B
EDG2:LSE iShares MSCI EM ESG Enhan.. 0.00 % 0.00 %

N/A

USD 4.37B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -54.90% 16% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.90% 16% F 6% D-
Trailing 12 Months  
Capital Gain -75.23% 20% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.23% 20% F 11% F
Trailing 5 Years  
Capital Gain -68.23% 58% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.23% 58% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain 13.91% 59% D- 61% D-
Dividend Return 13.91% 59% D- 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 72.97% 53% F 39% F
Risk Adjusted Return 19.07% 69% C- 54% F
Market Capitalization 7.10B 97% N/A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.